NASDAQ:ZFGN - Nasdaq -
0.99
-0.17 (-14.66%)
The current stock price of ZFGN is 0.99 null. In the past month the price increased by 26.16%. In the past year, price decreased by -45.9%.
Zafgen, Inc. is a biopharmaceutical company. The Company develops therapeutics for patients suffering from obesity and obesity-related disorders. Its lead product candidate includes Beloranib, an injection that is in Phase II clinical trials for the treatment of various indications comprising obesity and hyperphagia in Prader-Willi Syndrome patients, craniopharyngioma-associated obesity, and severe obesity in the general population. Zafgen, Inc. is headquartered in Cambridge, Massachusetts.
Zafgen Inc
3 Center Plaza Suite 610
BOSTON MA 02108
CEO: Jeffrey Hatfield
Phone: 617-622-4003
The current stock price of ZFGN is 0.99 null. The price decreased by -14.66% in the last trading session.
The exchange symbol of Zafgen Inc is ZFGN and it is listed on the Nasdaq exchange.
ZFGN stock is listed on the Nasdaq exchange.
Zafgen Inc (ZFGN) has a market capitalization of 37.10M null. This makes ZFGN a Nano Cap stock.
Zafgen Inc (ZFGN) has a support level at 0.84 and a resistance level at 1.1. Check the full technical report for a detailed analysis of ZFGN support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
ZFGN does not pay a dividend.
Zafgen Inc (ZFGN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.81).
ChartMill assigns a technical rating of 5 / 10 to ZFGN. When comparing the yearly performance of all stocks, ZFGN is a bad performer in the overall market: 88.88% of all stocks are doing better.
ChartMill assigns a fundamental rating of 2 / 10 to ZFGN. ZFGN may be in some trouble as it scores bad on both profitability and health.
Over the last trailing twelve months ZFGN reported a non-GAAP Earnings per Share(EPS) of -0.81. The EPS increased by 52.91% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -48.7% | ||
ROE | N/A | ||
Debt/Equity | 0.26 |
ChartMill assigns a Buy % Consensus number of 60% to ZFGN. The Buy consensus is the average rating of analysts ratings from 2 analysts.